Fentanyl and Ticagrelor Interaction in Percutaneous Coronary Intervention
(FACTPCI Trial)
Trial Summary
What is the purpose of this trial?
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you've used P2Y12 inhibitors in the last 14 days or if you're on anticoagulants.
What data supports the idea that Fentanyl and Ticagrelor Interaction in Percutaneous Coronary Intervention is an effective drug?
The available research shows that Ticagrelor is a commonly used drug for heart conditions and is effective in reducing blood clots. One study compared Fentanyl and Morphine, two pain-relief drugs, and found that Fentanyl does not delay the action of Ticagrelor as much as Morphine does. This suggests that using Fentanyl with Ticagrelor might be more effective in heart procedures than using Morphine. Another study looked at Fentanyl and another pain-relief drug, Lignocaine, and found that both worked well with Ticagrelor in heart patients. These findings support the idea that Fentanyl and Ticagrelor together can be an effective treatment during heart procedures.12345
What safety data exists for the interaction of Fentanyl and Ticagrelor in PCI?
The provided research primarily discusses the safety and effects of Ticagrelor, particularly its use in acute coronary syndromes and PCI. Ticagrelor is known to cause bradyarrhythmias and has a 'black box' warning for bleeding risks. There is no specific mention of Fentanyl or its interaction with Ticagrelor in the provided studies. Therefore, while there is safety data on Ticagrelor, specific data on its interaction with Fentanyl in PCI is not covered in the provided research.12367
Is the drug Ticagrelor a promising treatment for patients undergoing Percutaneous Coronary Intervention?
Yes, Ticagrelor is a promising drug for patients undergoing Percutaneous Coronary Intervention because it is a commonly used oral medication that helps prevent blood clots by inhibiting platelet activity. This can be crucial in treating acute coronary syndrome and during procedures like PCI to ensure better blood flow and reduce the risk of heart attacks.24589
Eligibility Criteria
This trial is for individuals undergoing a heart procedure called PCI and can swallow pills. It's not for pregnant people, those who've taken certain blood thinners recently, have bleeding disorders, low platelets, bad kidney or liver function, or are allergic to the study drugs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Fentanyl and Ticagrelor during PCI to assess the interaction between crushed vs non-crushed Ticagrelor
Follow-up
Participants are monitored for platelet function after treatment
Treatment Details
Interventions
- Fentanyl
- Ticagrelor
Ticagrelor is already approved in United States, European Union for the following indications:
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Guthrie Clinic
Lead Sponsor